A task force of the National Psoriasis Foundation Medical Board was convened to evaluate treatment options for psoriasis in the setting of excessive alcohol intake. Consensus on treatment algorithms was achieved.
Background
Psoriasis is a chronic, inflammatory, multisystem disease in which alcohol abuse is higher than in the general population. Alcohol may exacerbate psoriasis and can complicate the choices for therapy given the potential for the combined toxicity of ethanol and treatment. Evidence-based data to guide clinicians in managing these challenging patients are quite limited.
Objective
Our aim was to create treatment recommendations to help dermatologists manage patients with psoriasis in the setting of excessive alcohol intake.
Methods
A literature review was conducted to examine treatment options for psoriasis in the setting of excessive alcohol consumption.
Results
Treatment should be dictated by the severity of disease and any patient comorbidities. First-line choices for extensive disease include phototherapy with narrowband ultraviolet B and photochemotherapy with psoralen plus ultraviolet A, as well as the tumor necrosis factor-alpha inhibitors adalimumab and infliximab. Second-line choices are acitretin, alefacept, cyclosporine, etanercept, and ustekinumab. A third-line choice would be methotrexate. Physicians should be vigilant to check liver function tests regularly.
Limitations
There are few studies examining treatment options for psoriasis in the setting of excessive alcohol consumption. Thus, these recommendations are based on experience and expert opinions.
Conclusion
Management of psoriasis in the setting of excessive alcohol consumption requires a thorough understanding of the treatment options that are available. Therapy should be based on the extent of the disease balanced with patients' underlying comorbidities.
SchonM.P., BoehnckeW.H.Psoriasis. N Engl J Med.2005; 352(18): 1899–912.
2.
GelfandJ.M., WeinsteinR., PorterS.B., NeimannA.L., BerlinJ.A., MargolisD.J.Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol.2005; 141(12): 1537–41.
3.
SternR.S., NijstenT., FeldmanS.R., MargolisD.J., RolstadT.Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc.2004; 9(2): 136–9.
4.
NaldiL., ParazziniF., BreviA.Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol.1992; 127: 212–7.
5.
NaldiL., ChatenoudL., LinderD.Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol.2005; 12561–7.
6.
HigginsE.M., PetersT.J., du VivierA.W.Smoking, drinking and psoriasis. Br J Dermatol.1993; 129(6): 749–50.
7.
HigginsE.Alcohol, smoking and psoriasis. Clin Exp Dermatol.2000; 25(2): 107–10.
8.
PoikolainenK., ReunalaT., KarvonenJ., LauharantaJ., KarkkainenP.Alcohol intake: a risk factor for psoriasis in young and middle aged men?BMJ.1990; 300(6727): 780–3.
9.
FarkasA., KemenyL.Psoriasis and alcohol: is cutaneous ethanol one of the missing links?Br J Dermatol.2010; 162: 711–6.
10.
OckenfelsH.M., Keim-MaasC., FunkR., NussbaumG., GoosM.Ethanol enhances the IFN-gamma, TGF-alpha and IL-6 secretion in psoriatic co-cultures. Br J Dermatol.1996; 135(5): 746–51.
11.
HigginsE.M., du VivierA.W.Alcohol and the skin. Alcohol.1992; 27(6): 595–602.
12.
KawaguchiM., MitsuhashiY., KondoS.Overexpression of tumour necrosis factor-alpha-converting enzyme in psoriasis. Br J Dermatol.2005; 152: 915–9.
13.
SerwinA.B., SokolowskaM., DylejkoE., ChodynickaB.Tumour necrosis factor alpha converting enzyme and soluble TNF-alpha receptor type 1 in psoriasis patients in relation to the chronic alcohol consumption. J Eur Acad Dermatol Venereol.2008; 22: 712–7.
14.
NaldiL.Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy.2004; 3: 121–8.
15.
DawsonD.A., LiT.K., GrantB.F.A prospective study of risk drinking: at risk for what?Drug Alcohol Depend.2008; 95(1-2): 62–72.
16.
HasinD.S., StinsonF.S., OgburnE., GrantB.F.Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry.2007; 64(7): 830–2.
United States Department of Agriculture and United States Department of Health and Human Services. Chapter 9 – Alcoholic Beverages. In: Dietary Guidelines for Americans.Washington, DC: US Government Printing Office; 2005, pp. 43–6. Available at: http://www.health.gov/DIETARYGUIDELINES/dga2005/document/html/chapter9.htm. Accessed December 14, 2010.
19.
QureshiA.A., DominguezP.L., ChoiH.K., HamJ., CurhanG.Alcohol intake and risk of incident psoriasis in US women. Arch Dermatol.2010; 146: 1364–9.
MenterA., KormanN.J., ElmetsC.A.Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol.2010; 62: 114–35.
22.
SharmaP., KumarA., SharmaB.C., SarinS.K.Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial. J Hepatol.2009; 50: 584–91.
23.
ManciniS., AmorottiE., VecchioS., Ponz de LeonM., RoncucciL.Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med.2010; 5: 193–200.
24.
BoetticherN.C., PeineC.J., KwoP.A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology.2008; 135: 1953–60.
25.
KoutrubaN., EmerJ., LebwohlM.Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Ther Clin Risk Manage.2010; 6: 123–141.
26.
LarsenF.G., JakobsenP., KnudsenJ.Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol.1993; 100: 623–7.
PaulM.D., ParfreyP.S., SmartM., GaultH.The effect of ethanol on serum cyclosporine A levels in renal transplant recipients. Am J Kidney Dis.1987; 10: 133–5.
29.
Whiting-O'KeefeQ.E., FyeK.H., SackK.D.Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med.1991; 90: 711–6.
30.
MalatjalianD.A., RossJ.B., WiliamsC.N., ColwellS.J., EastwoodB.J.Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes, and alcohol consumption during long term follow-up. Can J Gastroenterol.1996; 10: 369–75.
31.
RosenbergP., UrwitzH., JohannessonA.Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol.2007; 46: 1111–8.
CoffinC.S., FraserH.F., PanaccioneR., GhoshS.Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis.2011; 17: 479–84.
34.
Garcia AparicioA.M., ReyJ.R., SanzA.H., AlvarezJ.S.Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol.2007; 26: 811–3.
35.
KlugerN., GirardC., GuillotB., BessisD.Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol.2009; 89: 332–3.
36.
ThiefinG., MoreletA., HeurgueA., DieboldM.D., EschardJ.P.Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine.2008; 75: 737–9.
37.
PoulinY., TherienG.Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review. J Cutan Med Surg.2010; 14: 100–4.
38.
WahieS., AlexandroffA., ReynoldsN.J.Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol.2006; 31: 460–1.
39.
MassarottiM., MarasiniB.Successful treatment with etanercept of a patient with psoriatic arthritis after adalimumab-related hepatotoxicity. Int J Immunopathol Pharmacol.2009; 22: 547–9.
40.
CarlsenK.M., RiisL., MadsenO.R.Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol.2009; 28: 1001–3.
41.
BeckerH., WillekeP., DomschkeW., GaubitzM.Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol.2008; 27: 1597–8.
42.
Ramos-CasalsM., Brito-ZeronP., SotoM.J., CuadradoM.J., KhamashtaM.A.Autoimmune disease induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol.2008; 22: 847–61.
43.
PetersonJ.R., HsuF.C., SimkinP.A., WenerM.H.Effect of tumor necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis.2003; 62: 1078–82.
44.
MichelM., DuvouxC., HezodeC., CherquiD.Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol.2003; 30: 1624–5.
45.
MainiR., St ClairE.W., BreedveldF.Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concominant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet.1999; 354: 1932–9.
46.
HanauerS.B., FeaganB.G., LichtensteinG.R.ACCENT I Study Group. Maintenance infliximab for Crohn's Disease: the ACCENT I randomised trial. Lancet.2002; 359: 1541–9.
47.
GottliebA.B., MathesonR.T., LoweN.A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol.2003; 139: 1627–32.
48.
LeonardiC.L., PowersJ.L., MathesonR.T.Etanercept as monotherapy in patients with psoriasis. N Engl J Med.2003; 349: 2014–22.
49.
MenterA., TyringS.K., GordonK., KimballA.B.Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol.2008; 58: 106–15.
SaleemG., LiS.C., MacPhersonB.R., CooperS.M.Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles, et al. Arthritis Rheum.2001; 44: 1966–8.
53.
GermanoV., Picchianti DiamantiA., BaccanoG., De FrancescoV., StoppinoG., PanellaC.Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis.2005; 64: 1519–20.
54.
IerardiE., ValleN.D., NacchieroM.C.Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig.2006; 26: 673–6.
Lopez-TalaveraJ.C., MerrillW.W., GroszmannR.J.Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology.1995; 108: 761–7.
61.
Lopez-TalaveraJ.C., CadelinaG., OlchowskiJ., MerrillW., GroszmannR.J.Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology.1996; 23: 1616–21.
62.
TilgH., JalanR., KaserA.Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol.2003; 38: 419–25.
63.
MookerjeeR.P., SenS., DaviesN.A., HodgesS.J., WilliamsR., JalanR.Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut.2003; 52: 1182–7.
64.
SpahrL., Rubbia-BrandtL., FrossardJ.L.Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol.2002; 37: 448–55.
65.
KruegerG.G., LangleyR.G., LeonardiC.A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med.2007; 356: 580–92.
66.
DiCesareA., DiMeglioP., NestleF.O.The IL-23/Th17 Axis in the immunopathogenesis of psoriasis. J Invest Dermatol.2009; 129: 1339–50.
67.
LeonardiC.L., KimballA.B., PappEfficacy and safety of usetekinumab, a human interleukin 12/23 monoclonal antibody, in patgients with psoriasis: 76-week results from a ranomised, doublebline, placebo-controlled trial (PHOENIX 1). Lancet.2008; 371: 1675–84.
68.
PappK.A., LangleyR.G., LebwohlM.Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet.2008; 371: 1675–84.
69.
GriffithsC.E., StroberB.E., MenterA.Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med.2010; 362: 118–28.
70.
GottliebA., MenterA., MendelsohnA.Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial. Lancet.2009; 373(9664): 633–40.
71.
SandbornW.J., FeaganB.G., FedorakR.N.Ustekinumab Crohn's Disease Study Group: a randomized trial of ustekinumab, a human interleukin 12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology.2008; 135(4): 1130–41.
72.
BrindleyC.J.Over view of recent clinical pharmacokinetic studies with acitretin (Ro-1670, etretin). Dermatologica.1989; 178: 79–87.
LaugierJ.P., de SousaG., BunH., GeigerJ.M., SurberC., RahmaniR.Acitretin biotransformation into etretinate: role of ethanol on in vitro hepatic metabolism. Dermatology.1994; 188: 122–5.
CunninghamW.J.Side effect profile of retinoids. In: RoenigkH.H.Jr., MaibachH.I., editors. Psoriasis. 2nd ed. New York: Marcel Dekker; 1991. pp. 769–74.
77.
ReikD., HarveyG., ArmstrongR.B.Acitretin (Ro 10-1670) Investigational Drug Brochure Addendum. Jan 20, 1989. Research report N-130514. Data on file, Roche Laboratories.
78.
van DitzhuijsenT.J., van HaelstU.J., van Dooren-GreebeR.J., van de KerkhofP.C., YapS.H.Severe hepatotoxic reaction with progression to cirrhosis after use of a novel retinoid (acitretin). J Hepatol.1990; 11: 185–8.
79.
RoenigkH.H., CallenJ.P., GuzzoC.A.Effects of acitretin on the liver. J Am Acad Dermatol.1999; 41: 584–8.
80.
KatzH.I., WaalenJ., LeachE.E.Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol.1999; 41: S7–12.
81.
KooJ.Y.M., LeeC.S., MaloneyJ.E.Cyclosporine and related drugs. In: WolvertonS.E., editor. Comprehensive Dermatologic Drug Therapy. 1st ed. Philadelphia: W. B. Saunders; 2001. pp. 205–29.
82.
RodgerS., TurneyJ.H., HaynesI., McMasterP., MichaelJ., AduD.Normal liver function in renal allograft patients treated with cyclosporine. Transplantation.1983; 36(4): 451–2.
83.
LoertacherR., WenkM., HarderF., BrunnerF., FollathF., ThielG.Hyperbilirubinemia and cyclosporin A levels in renal allograft patients. Lancet.1981; 2: 635–6.
84.
WelzA., ReichartB., UberfuhrP., KemkesB., KlinnerW.Cyclosporine as the main immunosuppressant in clinical heart transplantation: correlation of hepatotoxicity and nephrotoxicity. Transplant Proc.1984; 16: 1212–3.
85.
GulbisB., AdlerM., OomsH.A., DesmetJ.M., LeclercJ.L., PrimoG.Liver-function studies in heart-transplant recipients treated with cyclosporin A. Clin Chem.1988; 34: 1772–4.
86.
WolfA., TrendelenburgC.F., Diez-FernandezC., PrietoP., CordierA.Role of glutathione in cyclosporine A in vitro hepatotoxicity. Transplant Proc.1994; 26: 2912–4.
87.
WolfA., TrendelenburgC.F., Diez-FernandezC.Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharm Exp Ther.1997; 280: 1328–34.
88.
AndresD., SanzN., ZaragozaA., AlvarezA.M., CascalesM.Changes in antioxidant defence systems induced by cyclosporine A in cultures of hepatocytes from 2- and 12-month-old rats. Biochem Pharmacol.2000; 59: 1091–100.
89.
Mostafavi-PourZ., ZalF., MonabatiA., VessalM.Protective effects of a combination of quercetin and vitamin E against cyclosporine A-induced oxidative stress and hepatotoxicity in rats. Hepatol Res.2008; 38: 385–92.
AshtonR.E., Millward-SadlerG.H., WhiteJ.E.Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol.1982; 79: 229–32.
92.
ZachariaeH., KragballeK., SogaardH.Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment. Br J Dermatol.1980; 102: 407–12.
93.
BrendsM.A., SnoekJ., de JongE.M.Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. Aliment Pharmacol Ther.2006; 24: 805–11.
94.
ZachariaeH.Liver biopsies and methotrexate: a time for reconsideration?J Am Acad Dermatol.2000; 42: 531–4.
95.
Van Dooren-GreebeR.J., KuijpersA.L., MulderJ., De BooT., Van de KerkhofP.C.Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol.1994; 130: 204–10.
96.
BoffaM.J., ChalmersR.J.Methotrextae for psoriasis. Clin Exp Dermatol.1996; 21: 399–408.
97.
KalbR.E., StroberB., WeinsteinG., LebwohlM.Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol.2009; 60: 824–37.
98.
NyforsA.Liver biopsies from psoriatics related to methotrexate therapy. 3. Findings in post-methotrexate liver biopsies from 160 psoriatics. Acta Pathol Microbiol Scand A.1977; 85: 511–8.
99.
HerronM.D., HinckleyM., HoffmanM.S.Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol.2005; 141: 1527–34.
100.
LangmanG., HallP., ToddG.Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol.2001; 16: 1395–401.
